Exploring the Rare Diseases Global Clinical Trials Landscape: Unveiling Challenges, Trends, and Promising Advances

Rare diseases, as defined by the World Health Organization (WHO), are a group of debilitating disorders that affect fewer than 1 in every 1,000 individuals and typically are life-threatening. Despite their individual rarity, the combined prevalence of these conditions is notable, and is estimated to affect 3.5%-6% of the global population, which is approximately 260-440 million people at any given time. This staggering figure emphasizes the critical importance of rare diseases as a distinct category within the medical landscape, particularly due to the significant unmet medical needs they represent.

Rare diseases present a common challenge across diverse geographies. Around 260 million people, primarily children, live in the Asia-Pacific (APAC) region, underscoring the critical need for attention and action. Meanwhile, the European Union (EU) has over 30 million people suffering from rare diseases, and the United States (US) has a comparable figure of over 30 million people suffering from these ailments.

The landscape of rare diseases is fraught with challenges. A lack of knowledge and expertise, along with a delayed diagnosis, aggravates the suffering of the individuals affected. These roadblocks are especially daunting in chronic diseases where an absolute cure is yet elusive.

Notably, the oncology sector takes centre stage as the leading orphan drug therapeutic area in clinical trials. Non-oncology categories such as haematology, the central nervous system, infectious diseases, respiratory diseases, and gastrointestinal disorders, on the other hand, account for a sizable percentage of the non-oncology orphan drug market.

Among the most common rare diseases, PNH, Multiple Myeloma, and Chronic Lymphocytic Leukaemia (CLL) are among the most prevalent applications in the orphan drug market. Non-Hodgkin lymphoma (NHL), acute myeloid leukaemia (AML), and pancreatic cancer are among the most recognised disorders in terms of orphan drug designations.

From 2018 through 2022, the landscape of rare disease clinical trials is characterised by a constant upward trajectory, with over 16,000 studies performed globally. Surprisingly, biologic drugs account for more than 45% of the drugs in development. Geographically, APAC has the fastest 5-year compound annual growth rate (CAGR), with North America and Europe accounting for the majority of trials. The United States, Mainland China, and many European countries are notable contributors within the global rare disease clinical trials landscape.

The distribution of rare disease trials across geographies reveals an intriguing pattern. China is the leader in single-country rare disease studies in APAC. The United States plays a comparable role in North America, while the United Kingdom, Germany, and France lead the push in Europe. Interestingly, early-phase trials exceed mid- and late-phase trials, while ongoing trials outnumber completed ones, highlighting the importance of continuous research and development efforts.

Oncology is the most investigated therapeutic area across each region, with significant subjects of study including pancreatic cancer, multiple myeloma, blood cancers, and multiple sclerosis. Patient recruitment reveals an interesting picture, with APAC having the shortest trial period and the highest recruitment rate.

Oncology and genetic diseases such as cystic fibrosis and spinal muscular atrophy are leading the way in the field of orphan drugs. Small molecule drugs, monoclonal antibodies, CAR-T cell therapy, gene therapy, enzyme replacement therapy, protein replacement therapy, and antisense oligonucleotides (ASOs) are examples of new approaches in rare disease therapy development.

North American venture funding, particularly in the United States, exceeds that of APAC and the EU, showing the region's dedication to bolstering rare disease research and treatment. Biotech firms are rapidly extending their biologic drug pipelines, increasing the chance of future approvals.

As we look ahead, the need for advancing scientific investigation and testing throughout the world remains unrelenting. Contract Research Organisations (CROs) like Novotech are critical in accelerating rare disease drug development by leveraging their skills to overcome challenging problems and catalyse progress.

In summary, the landscape of rare diseases clinical trials is characterised by its inherent challenges, trends, and prospective breakthroughs. As collaborators from all locations work together to solve the mysteries of these unexplained disorders, the joint effort emphasises the crucial significance of addressing unmet medical needs. The horizon is bright with the possibility of extending treatment choices and improving the lives of millions impacted by rare diseases by adopting breakthrough therapeutics, leveraging venture funding, and capitalising on the scientific expertise of organisations like Novotech.

Download the whole whitepaper, an excellent resource for anybody interested in the world of rare diseases and potential treatments and discovering more about this complex landscape and getting a thorough analysis